Other factors that affected the comparison of docetaxel and paclitaxel were treatment early stops or regimen changes due to severe side effects, as well as tumor HER2 status changes (negative to positive, NP-12) during the treatment period (SI Appendix, List S1). This evidence concerns the gene ERBB2 and neoplasm.